Form 4: Vanda Pharmaceuticals CEO Acquires 10,000 Shares
SEC Form 4 Filing
Vanda Pharmaceuticals' CEO, Mihael Hristos Polymeropoulos, purchased 10,000 shares of common stock at $4.76 per share on February 27, 2025.
Summary
- On February 27, 2025, Mihael Hristos Polymeropoulos, the President and CEO, Chairman of the Board, and a director of Vanda Pharmaceuticals Inc., acquired 10,000 shares of common stock.
- The purchase price was $4.76 per share.
- Following this transaction, Polymeropoulos directly owns 2,351,730 shares of Vanda Pharmaceuticals Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally a good sign, but the document itself is simply a regulatory filing.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider transactions are closely monitored as they can provide insights into a company's performance and future prospects. A purchase by the CEO is often seen as a positive signal.
Stakeholder Impact
- The CEO's stock purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of transaction: CEO purchased 10,000 shares of VNDA at $4.76 per share. |
| 02/27/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.